<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Gastrointestinal</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Korea roundup: Alteogen, Celltrion lead biotech deals</title>
      <description>
        <![CDATA[Subcutaneous formulation technology, microbiomes and oncological assets drove dealmaking in South Korea’s biotech sector this week.&nbsp;]]>
      </description>
      <guid>http://www.bioworld.com/articles/730087</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730087-korea-roundup-alteogen-celltrion-lead-biotech-deals</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Celltrion-Kobiolabs-3-26.webp?t=1774632497" type="image/jpeg" medium="image" fileSize="738862">
        <media:title type="plain">Seo Jin-seok of Celltrion (right) with Ko Kwang-pyo of Kobiolabs (left)</media:title>
        <media:description type="plain">Seo Jin-seok, CEO, Celltrion (right) with Ko Kwang-pyo, founder and CEO, Kobiolabs (left).</media:description>
      </media:content>
    </item>
    <item>
      <title>US FDA says no, again, to Vanda’s tradipitant in gastroparesis</title>
      <description>
        <![CDATA[The U.S. path forward is narrowing for Vanda Pharmaceuticals Inc.’s tradipitant as a treatment for gastroparesis, a serious disorder for which there’s been no new treatment in several decades.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729966</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729966-us-fda-says-no-again-to-vandas-tradipitant-in-gastroparesis</link>
    </item>
    <item>
      <title>HHEX emerges as a potential IBD target</title>
      <description>
        <![CDATA[In recent work, researchers from Shanghai Jiaotong University School of Medicine and Shanghai Colorectal Cancer Research Center reported that the transcription factor hematopoietically expressed homeobox (HHEX) promotes tumorigenesis in colitis-associated colorectal cancer. In a new paper, the team aimed to further characterize the biological function and potentially dysregulated mechanisms of HHEX during intestinal inflammation, which remained largely unexplored.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730001</guid>
      <pubDate>Fri, 27 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730001-hhex-emerges-as-a-potential-ibd-target</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Gastrointestinal-IBD-Crohns.webp?t=1730736512" type="image/jpeg" medium="image" fileSize="256580">
        <media:title type="plain">Illustration for inflammatory bowel disease</media:title>
      </media:content>
    </item>
    <item>
      <title>Korea roundup: Alteogen, Celltrion lead biotech deals</title>
      <description>
        <![CDATA[Subcutaneous (SC) formulation technology, microbiomes and oncological assets drove dealmaking in South Korea’s biotech sector this week.&nbsp;]]>
      </description>
      <guid>http://www.bioworld.com/articles/729906</guid>
      <pubDate>Thu, 26 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729906-korea-roundup-alteogen-celltrion-lead-biotech-deals</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Celltrion-Kobiolabs-3-26.webp?t=1774632497" type="image/jpeg" medium="image" fileSize="738862">
        <media:title type="plain">Seo Jin-seok of Celltrion (right) with Ko Kwang-pyo of Kobiolabs (left)</media:title>
        <media:description type="plain">Seo Jin-seok, CEO, Celltrion (right) with Ko Kwang-pyo, founder and CEO, Kobiolabs (left).</media:description>
      </media:content>
    </item>
    <item>
      <title>GSK’s IBAT inhibitor wins US FDA nod for cholestatic pruritus </title>
      <description>
        <![CDATA[With the U.S. FDA’s approval of GSK plc’s ileal bile acid transporter (IBAT) inhibitor, Lynavoy (linerixibat), patients with primary biliary cholangitis no longer need off-label treatments for a debilitating internal itch symptom called cholestatic pruritus.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729745</guid>
      <pubDate>Thu, 19 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729745-gsks-ibat-inhibitor-wins-us-fda-nod-for-cholestatic-pruritus</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Wood-approved-stamp-red.webp?t=1670969940" type="image/png" medium="image" fileSize="323015">
        <media:title type="plain">Red wooden approved stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>R1’s $77.5M series A to fund CKD trial of oral phosphate inhibitor</title>
      <description>
        <![CDATA[Newco R1 Therapeutics Inc. has launched with an oversubscribed $77.5 million series A, providing the means to take AP-306, a potentially first-in-class hyperphosphatemia therapy through phase IIb development in patients with chronic kidney disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729551</guid>
      <pubDate>Tue, 17 Mar 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729551-r1s-775m-series-a-to-fund-ckd-trial-of-oral-phosphate-inhibitor</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Nephrology/kidney-nephrology.webp?t=1589217921" type="image/png" medium="image" fileSize="520589">
        <media:title type="plain">Kidneys</media:title>
      </media:content>
    </item>
    <item>
      <title>KIST and Neocannbio report new NO production inhibitors</title>
      <description>
        <![CDATA[The Korea Institute of Science and Technology (KIST) and Neocannbio Co. Ltd. have jointly identified compounds acting as nitric oxide (NO) production inhibitors with potential for the treatment of inflammatory bowel disease (IBD).]]>
      </description>
      <guid>http://www.bioworld.com/articles/729334</guid>
      <pubDate>Wed, 04 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729334-kist-and-neocannbio-report-new-no-production-inhibitors</link>
    </item>
    <item>
      <title>Jiuyuan seeks approval of Wegovy biosimilar in China</title>
      <description>
        <![CDATA[China’s National Medical Products Administration has accepted for review Jiuyuan Genetic Biopharmaceutical Co. Ltd.’s drug application for Jikeqin, a biosimilar product to Novo Nordisk A/S’s Wegovy (semaglutide) for obesity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729318</guid>
      <pubDate>Tue, 03 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729318-jiuyuan-seeks-approval-of-wegovy-biosimilar-in-china</link>
    </item>
    <item>
      <title>GPR68 negative allosteric modulator ameliorates ulcerative colitis</title>
      <description>
        <![CDATA[G-protein coupled receptor 68 (GPR68) is an acid-sensing protein receptor that has been implicated in inflammatory bowel disease (IBD) pathogenesis by its modulation of the inflammatory response and fibrosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729119</guid>
      <pubDate>Fri, 27 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729119-gpr68-negative-allosteric-modulator-ameliorates-ulcerative-colitis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Gastrointestinal-vector-framework.webp?t=1739806991" type="image/jpeg" medium="image" fileSize="232822">
        <media:title type="plain">Illustration of intestinal track</media:title>
      </media:content>
    </item>
    <item>
      <title>SIK2 inhibitor mitigates pathology in ulcerative colitis models </title>
      <description>
        <![CDATA[Salt-inducible kinase 2 (SIK2) is a serine/threonine kinase that regulates transcriptional programs in myeloid cells by phosphorylating transcriptional coregulators. In macrophages, SIK2 promotes the expression of proinflammatory cytokines and contributes to the balance between inflammatory and regulatory responses. Researchers from Nimbus Therapeutics LLC presented the preclinical efficacy of NTX-147, a SIK2 selective inhibitor, in ex vivo models of ulcerative colitis (UC).]]>
      </description>
      <guid>http://www.bioworld.com/articles/729114</guid>
      <pubDate>Fri, 27 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729114-sik2-inhibitor-mitigates-pathology-in-ulcerative-colitis-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/3D-illustration-of-human-digestive-system.webp?t=1709246262" type="image/jpeg" medium="image" fileSize="171684">
        <media:title type="plain">3D illustration of human digestive system</media:title>
      </media:content>
    </item>
    <item>
      <title>Jiuyuan seeks approval of Wegovy biosimilar in China</title>
      <description>
        <![CDATA[China’s National Medical Products Administration has accepted for review Jiuyuan Genetic Biopharmaceutical Co. Ltd.’s drug application for Jikeqin, a biosimilar product to Novo Nordisk A/S’s Wegovy (semaglutide) for obesity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729245</guid>
      <pubDate>Thu, 26 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729245-jiuyuan-seeks-approval-of-wegovy-biosimilar-in-china</link>
    </item>
    <item>
      <title>Targeting OGFOD1 improves hepatic ischemia-reperfusion injury</title>
      <description>
        <![CDATA[Hepatic ischemia-reperfusion injury (HIRI) is a severe pathologic condition associated with poor outcomes when individuals suffer from hemorrhagic shock, liver resection or transplantation surgery, leading to severe liver impairment and sometimes dysfunction in other organs. Chinese researchers have explored the potential of prolyl 3-hydroxylase OGFOD1 as a target for HIRI management, since it has been reported as a crucial regulator of gene expression, especially for translation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729058</guid>
      <pubDate>Thu, 26 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729058-targeting-ogfod1-improves-hepatic-ischemia-reperfusion-injury</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-illustration.webp?t=1613674462" type="image/png" medium="image" fileSize="432664">
        <media:title type="plain">Liver illustration</media:title>
        <media:description type="plain">Credit: Georgia State University</media:description>
      </media:content>
    </item>
    <item>
      <title>Vivtex’s oral drug delivery approach draws Novo in $2.1B deal</title>
      <description>
        <![CDATA[Coming off a U.S. FDA approval of the first GLP-1 in pill format, Novo Nordisk A/S leaned further into oral drug delivery efforts, partnering with Vivtex Corp. to develop next-generation oral formulations of peptide and protein therapeutics in a potential $2.1 billion deal that marks the highest-profile news for Vivtex since the firm spun out of MIT in 2018.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729200</guid>
      <pubDate>Wed, 25 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729200-vivtexs-oral-drug-delivery-approach-draws-novo-in-21b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/GI-ORIS-pic-Vivtex-2-25.webp?t=1772058346" type="image/jpeg" medium="image" fileSize="528373">
        <media:title type="plain">GI-ORIS-pic-Vivtex-2-25.jpg</media:title>
        <media:description type="plain">GI-ORIS, or “GI tract on a chip” screening system.
Credit: Vivtex Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Spyre reports enhanced efficacy of anti-TL1A and anti-IL-23 combination </title>
      <description>
        <![CDATA[Researchers from Spyre Therapeutics Inc. reported on the therapeutic efficacy of combining anti-TL1A and anti-IL-23 antibodies in preclinical models of colitis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729037</guid>
      <pubDate>Wed, 25 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729037-spyre-reports-enhanced-efficacy-of-anti-tl1a-and-anti-il-23-combination</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/IBD-ulcerative-colitis.webp?t=1668182386" type="image/png" medium="image" fileSize="1246429">
        <media:title type="plain">Gastrointestinal system with ulcerative colitis.</media:title>
      </media:content>
    </item>
    <item>
      <title>GS-8670 restores epithelial barrier function in IBD models </title>
      <description>
        <![CDATA[The farnesoid X receptor (FXR) is a nuclear receptor that plays a central role in bile acid regulation, intestinal barrier integrity, immune modulation and microbiome balance, all key factors involved in the development of inflammatory bowel disease (IBD). Researchers from Gilead Sciences Inc. reported the effects of GS-8670, an FXR agonist, in models of colitis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729035</guid>
      <pubDate>Wed, 25 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729035-gs-8670-restores-epithelial-barrier-function-in-ibd-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/IBD-inflammatory-bowel-disease-Crohns-Colitis.webp?t=1745258495" type="image/jpeg" medium="image" fileSize="193405">
        <media:title type="plain">Illustration of intestines with inflammation</media:title>
      </media:content>
    </item>
    <item>
      <title>Ailux characterizes ALX-001 for IMIDs</title>
      <description>
        <![CDATA[Researchers from Shanghai Ailux Biotechnology Co. Ltd. have disclosed preclinical data regarding their humanized bispecific antibody ALX-001 targeting TL1A and IL-23 for the potential treatment of immune-mediated inflammatory diseases (IMIDs).]]>
      </description>
      <guid>http://www.bioworld.com/articles/729018</guid>
      <pubDate>Tue, 24 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729018-ailux-characterizes-alx-001-for-imids</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Macrophage-releasing-cytokines-illustration.webp?t=1771947007" type="image/jpeg" medium="image" fileSize="590737">
        <media:title type="plain">Illustration of macrophage releasing cytokines</media:title>
      </media:content>
    </item>
    <item>
      <title>Novo’s next-gen obesity drug fails to beat Lilly's Zepbound</title>
      <description>
        <![CDATA[Shares in Novo Nordisk A/S took another battering after the company announced its next-generation obesity drug Cagrisema failed to show noninferiority to Eli Lilly and Co. Inc.’s Zepbound in an open-label comparator study.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729176</guid>
      <pubDate>Mon, 23 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729176-novos-next-gen-obesity-drug-fails-to-beat-lillys-zepbound</link>
    </item>
    <item>
      <title>Stoked Bio licenses rights to enterololin for Crohn’s disease</title>
      <description>
        <![CDATA[Stoked Bio Inc. has secured an exclusive global license from McMaster University for the patents covering enterololin, a promising narrow-spectrum antibiotic.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728937</guid>
      <pubDate>Thu, 19 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728937-stoked-bio-licenses-rights-to-enterololin-for-crohns-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-NIAID-Scanning-electron-micrograph-of-Escherichia-coli.webp?t=1667837128" type="image/png" medium="image" fileSize="2031153">
        <media:title type="plain">Colorized scanning electron micrograph of E. coli bacteria.</media:title>
        <media:description type="plain">Escherichia coli bacteria. Credit: National Institute of Allergy and Infectious Diseases, NIH
</media:description>
      </media:content>
    </item>
    <item>
      <title>Human-relevant models lining up to replace animal tests</title>
      <description>
        <![CDATA[The pressure to replace animal testing with human-relevant assays that are more predictive of human-drug responses has now reached a tipping point, and there is a movement toward greater acceptance of these potentially more translatable tests.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728849</guid>
      <pubDate>Thu, 12 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728849-human-relevant-models-lining-up-to-replace-animal-tests</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Lab-mouse.webp?t=1672351570" type="image/png" medium="image" fileSize="276813">
        <media:title type="plain">Lab mouse</media:title>
      </media:content>
    </item>
    <item>
      <title>Discovery and characterization of FXR partial agonists for the treatment of MASH</title>
      <description>
        <![CDATA[The farnesoid X receptor (FXR) is a nuclear receptor predominantly expressed in the liver, intestine and kidney. FXR is crucially involved in regulating bile acid homeostasis, controlling inflammatory responses in the liver, and regulating lipid and glucose metabolism. Therefore, FXR plays a role in regulating metabolic dysfunction-associated steatohepatitis (MASH) and has been proposed as a promising target for MASH drug development.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728816</guid>
      <pubDate>Thu, 12 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728816-discovery-and-characterization-of-fxr-partial-agonists-for-the-treatment-of-mash</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-collage.webp?t=1663106040" type="image/png" medium="image" fileSize="360588">
        <media:title type="plain">Liver illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Microbiotica reports positive phase Ib data for live microbiome therapeutic</title>
      <description>
        <![CDATA[Microbiome specialist Microbiotica Ltd. announced positive data from a phase Ib study of MB-310, an orally administered live biotherapeutic product for treating ulcerative colitis, with 12 of 19 treated patients achieving clinical remission, compared to three of 10 patients in the placebo arm.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728728</guid>
      <pubDate>Wed, 11 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728728-microbiotica-reports-positive-phase-ib-data-for-live-microbiome-therapeutic</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Gastrointestinal-vector-framework.webp?t=1739806991" type="image/jpeg" medium="image" fileSize="232822">
        <media:title type="plain">Illustration of intestinal track</media:title>
      </media:content>
    </item>
    <item>
      <title>Madrigal licenses six Ribo siRNA programs</title>
      <description>
        <![CDATA[Madrigal Pharmaceuticals Inc. has signed an exclusive global license agreement with Suzhou Ribo Life Science Co. Ltd. and its subsidiary Ribocure Pharmaceuticals AB for six preclinical small interfering RNA (siRNA) programs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728784</guid>
      <pubDate>Wed, 11 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728784-madrigal-licenses-six-ribo-sirna-programs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/siRNA.webp?t=1590081687" type="image/png" medium="image" fileSize="147005">
        <media:title type="plain">siRNA bound to mRNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Iambic raises the bard in AI, pens $1.7B Takeda deal</title>
      <description>
        <![CDATA[Iambic Therapeutics Inc.’s multiyear technology and discovery pact with Takeda Pharmaceutical Co. Ltd. could help the San Diego-based firm advance its own pipeline in a big way.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728804</guid>
      <pubDate>Tue, 10 Feb 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728804-iambic-raises-the-bard-in-ai-pens-17b-takeda-deal</link>
    </item>
    <item>
      <title>Iambic raises the bard in AI, pens $1.7B Takeda deal</title>
      <description>
        <![CDATA[Iambic Therapeutics Inc.’s multiyear technology and discovery pact with Takeda Pharmaceutical Co. Ltd. could help the San Diego-based firm advance its own pipeline in a big way.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728702</guid>
      <pubDate>Mon, 09 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728702-iambic-raises-the-bard-in-ai-pens-17b-takeda-deal</link>
    </item>
    <item>
      <title>Innocare’s VAV1 degrader ICP-538 cleared for clinic in China</title>
      <description>
        <![CDATA[Beijing Innocare Pharma Tech Co. Ltd. has gained IND clearance in China to conduct clinical trials of ICP-538, an orally administered molecular glue degrader targeting VAV1, which is a key protein downstream of T-cell and B-cell receptors. ICP-538 is being studied for the treatment of autoimmune diseases, such as inflammatory bowel disease, systemic lupus erythematosus and multiple sclerosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728741</guid>
      <pubDate>Mon, 09 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728741-innocares-vav1-degrader-icp-538-cleared-for-clinic-in-china</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/molecular-science-research-art-2.webp?t=1749649165" type="image/jpeg" medium="image" fileSize="145862">
        <media:title type="plain">Art concept for molecular glue degradation</media:title>
      </media:content>
    </item>
    <item>
      <title>More biopharma IPOs: Agomab raises $200M, Spyglass gets $150M</title>
      <description>
        <![CDATA[Another two biopharma companies priced IPOs on Nasdaq to raise a combined $350 million, becoming the fourth and fifth firms to debut on U.S. markets in 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728763</guid>
      <pubDate>Fri, 06 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728763-more-biopharma-ipos-agomab-raises-200m-spyglass-gets-150m</link>
    </item>
    <item>
      <title>Novel JAK1/2 PROTAC degrader effectively improves IBD</title>
      <description>
        <![CDATA[Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, is a chronic immune-mediated inflammatory disorder with limited long-term therapeutic options. Proteolysis-targeting chimeras (PROTACs) offer a promising strategy for IBD by enabling selective degradation of disease-relevant proteins and potentially improving efficacy and safety.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728456</guid>
      <pubDate>Mon, 02 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728456-novel-jak1-2-protac-degrader-effectively-improves-ibd</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Gastrointestinal-inflammatory-bowel-disease-IBD-Crohn.webp?t=1706553250" type="image/jpeg" medium="image" fileSize="247467">
        <media:title type="plain">Art concept for inflammation in the intestines</media:title>
      </media:content>
    </item>
    <item>
      <title>Sinorda Biomedicine and Wuxi Biologics collaborate on SND-006</title>
      <description>
        <![CDATA[Wuxi Biologics Co. Ltd. and Sinorda Biomedicine have established a strategic collaboration for the development and manufacturing of SND-006, a novel bispecific antibody, for the treatment of inflammatory bowel disease and other autoimmune diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728417</guid>
      <pubDate>Thu, 29 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728417-sinorda-biomedicine-and-wuxi-biologics-collaborate-on-snd-006</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/IBD-inflammatory-bowel-disease-Crohns-Colitis.webp?t=1745258495" type="image/jpeg" medium="image" fileSize="193405">
        <media:title type="plain">Illustration of intestines with inflammation</media:title>
      </media:content>
    </item>
    <item>
      <title>Boehringer nabs preclinical IBD bispecific in $1.2B Simcere pact</title>
      <description>
        <![CDATA[Boehringer Ingelheim International GmbH signed a €1.058 billion (US$1.26 billion) deal with Simcere Pharmaceutical Group Ltd. to license select rights to SIM-0709, a preclinical TL1A/IL-23p19-directed bispecific antibody targeting inflammatory bowel disease (IBD).]]>
      </description>
      <guid>http://www.bioworld.com/articles/728346</guid>
      <pubDate>Wed, 28 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728346-boehringer-nabs-preclinical-ibd-bispecific-in-12b-simcere-pact</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Green-and-red-bispecific-antibodies.webp?t=1741632039" type="image/jpeg" medium="image" fileSize="108053">
        <media:title type="plain">Green and red bispecific antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>Boehringer Ingelheim and Simcere partner on SIM-0709</title>
      <description>
        <![CDATA[Boehringer Ingelheim International GmbH and Simcere Pharmaceutical Group Ltd. have entered into a license and collaboration agreement to develop SIM-0709 for the treatment of inflammatory bowel disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728375</guid>
      <pubDate>Tue, 27 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728375-boehringer-ingelheim-and-simcere-partner-on-sim-0709</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/global-business-trade-deal.webp?t=1588276966" type="image/png" medium="image" fileSize="2119366">
        <media:title type="plain">Handshake with digital globe overlay</media:title>
      </media:content>
    </item>
  </channel>
</rss>
